Cytokine profiles associated with disease severity and prognosis of autoimmune pulmonary alveolar proteinosis. 2024

Keiichi Akasaka, and Masako Amano, and Tomohiko Nakamura, and Tomotaka Nishizawa, and Hideaki Yamakawa, and Shintaro Sato, and Ami Aoki, and Kenjiro Shima, and Hidekazu Matsushima, and Toshinori Takada
Department of Respiratory Medicine, Saitama Red Cross Hospital, 1-5 Shintoshin, Chuo-ku, Saitama, 330-8553, Japan; Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, 4132 Urasa, Minami Uonuma-shi, Niigata, 949-7302, Japan.

BACKGROUND Pulmonary alveolar proteinosis (PAP) is characterized by an abnormal accumulation of surfactants in the alveoli. Most cases are classified as autoimmune PAP (APAP) because they are associated with autoantibodies against granulocyte-macrophage colony-stimulating factor (GM-CSF). However, GM-CSF autoantibody levels are unlikely to correlate with the disease severity or prognosis of APAP. METHODS We collected clinical records and measured 38 serum cytokine concentrations for consecutive patients with APAP. After exclusion of 21 cytokines because of undetectable levels, 17 cytokine levels were compared between low and high disease severity scores (DSSs). We also compared whole lung lavage (WLL)-free survival with cut-off values defined by receiver operating characteristic (ROC) curves of cytokine levels and WLL administration at 11 months. RESULTS Nineteen patients with APAP were enrolled in the study. Five were classified as DSS 1 or 2, while the others were classified as DSS 4 or 5. Comparison between DSS 1-2 and 4-5 revealed that the concentrations of IP-10 and GRO increased in the latter groups (p < 0.05). Fifteen patients underwent WLL. Comparison between those who underwent WLL within 11 months and the others showed that IP-10 and TNF-α were tended to be elevated in the former group (p = 0.082 and 0.057, respectively). The cut-off values of IP-10, 308.8 pg/mL and TNF-α, 19.1 pg/mL, defined by the ROC curves, significantly separated WLL-free survivals with log-rank analyses (p = 0.005). CONCLUSIONS The concentrations of IP-10 and GRO may reflect the DSSs of APAP. A combination of IP-10 and TNF-α levels could be a biomarker to predict WLL-free survival.

UI MeSH Term Description Entries

Related Publications

Keiichi Akasaka, and Masako Amano, and Tomohiko Nakamura, and Tomotaka Nishizawa, and Hideaki Yamakawa, and Shintaro Sato, and Ami Aoki, and Kenjiro Shima, and Hidekazu Matsushima, and Toshinori Takada
March 2016, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG,
Keiichi Akasaka, and Masako Amano, and Tomohiko Nakamura, and Tomotaka Nishizawa, and Hideaki Yamakawa, and Shintaro Sato, and Ami Aoki, and Kenjiro Shima, and Hidekazu Matsushima, and Toshinori Takada
May 2022, American journal of respiratory and critical care medicine,
Keiichi Akasaka, and Masako Amano, and Tomohiko Nakamura, and Tomotaka Nishizawa, and Hideaki Yamakawa, and Shintaro Sato, and Ami Aoki, and Kenjiro Shima, and Hidekazu Matsushima, and Toshinori Takada
December 2005, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG,
Keiichi Akasaka, and Masako Amano, and Tomohiko Nakamura, and Tomotaka Nishizawa, and Hideaki Yamakawa, and Shintaro Sato, and Ami Aoki, and Kenjiro Shima, and Hidekazu Matsushima, and Toshinori Takada
February 2014, Respirology (Carlton, Vic.),
Keiichi Akasaka, and Masako Amano, and Tomohiko Nakamura, and Tomotaka Nishizawa, and Hideaki Yamakawa, and Shintaro Sato, and Ami Aoki, and Kenjiro Shima, and Hidekazu Matsushima, and Toshinori Takada
December 2013, Clinical immunology (Orlando, Fla.),
Keiichi Akasaka, and Masako Amano, and Tomohiko Nakamura, and Tomotaka Nishizawa, and Hideaki Yamakawa, and Shintaro Sato, and Ami Aoki, and Kenjiro Shima, and Hidekazu Matsushima, and Toshinori Takada
January 2015, Internal medicine (Tokyo, Japan),
Keiichi Akasaka, and Masako Amano, and Tomohiko Nakamura, and Tomotaka Nishizawa, and Hideaki Yamakawa, and Shintaro Sato, and Ami Aoki, and Kenjiro Shima, and Hidekazu Matsushima, and Toshinori Takada
March 2010, American journal of respiratory and critical care medicine,
Keiichi Akasaka, and Masako Amano, and Tomohiko Nakamura, and Tomotaka Nishizawa, and Hideaki Yamakawa, and Shintaro Sato, and Ami Aoki, and Kenjiro Shima, and Hidekazu Matsushima, and Toshinori Takada
January 2022, ERJ open research,
Keiichi Akasaka, and Masako Amano, and Tomohiko Nakamura, and Tomotaka Nishizawa, and Hideaki Yamakawa, and Shintaro Sato, and Ami Aoki, and Kenjiro Shima, and Hidekazu Matsushima, and Toshinori Takada
October 2022, Internal medicine (Tokyo, Japan),
Keiichi Akasaka, and Masako Amano, and Tomohiko Nakamura, and Tomotaka Nishizawa, and Hideaki Yamakawa, and Shintaro Sato, and Ami Aoki, and Kenjiro Shima, and Hidekazu Matsushima, and Toshinori Takada
June 2017, American journal of industrial medicine,
Copied contents to your clipboard!